Lonza is a leading supplier to the pharmaceutical, biotech and specialty ingredients markets.
The layoffs are a result of a companywide realignment as the it builds four cell and gene therapy centers in the U.S., the Netherlands and Singapore, a company spokesperson told BioPharma Dive.
The Maryland plant will shift its focus from cell therapy production to bioscience solutions.
The layoffs are expected to occur over a one-year period.
More articles on pharmacy:
Drug take back day is Oct. 27: 5 things to know
Amgen cuts list price of $14K-a-year cholesterol drug nearly 60%
Trump’s plan to lower prescription drug prices: 7 takeaways
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
